Zynex Inc. (OTCMKTS:ZYXI) CEO Sells $1,388,730.80 in Stock

Zynex Inc. (OTCMKTS:ZYXI) CEO Thomas Sandgaard sold 131,260 shares of the business’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $10.58, for a total value of $1,388,730.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Thomas Sandgaard also recently made the following trade(s):

  • On Monday, June 10th, Thomas Sandgaard sold 50,000 shares of Zynex stock. The stock was sold at an average price of $8.88, for a total value of $444,000.00.
  • On Thursday, June 6th, Thomas Sandgaard sold 35,868 shares of Zynex stock. The stock was sold at an average price of $8.00, for a total value of $286,944.00.
  • On Tuesday, May 21st, Thomas Sandgaard sold 9,045 shares of Zynex stock. The stock was sold at an average price of $8.00, for a total value of $72,360.00.

Shares of OTCMKTS:ZYXI opened at $10.34 on Thursday. Zynex Inc. has a 52-week low of $2.46 and a 52-week high of $11.75. The stock’s fifty day simple moving average is $8.75 and its 200-day simple moving average is $6.86. The company has a market capitalization of $326.53 million, a P/E ratio of 47.00 and a beta of 1.05.



Zynex (OTCMKTS:ZYXI) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.06 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.06. Zynex had a return on equity of 152.81% and a net margin of 33.33%. The business had revenue of $10.30 million for the quarter, compared to the consensus estimate of $9.84 million. Sell-side analysts forecast that Zynex Inc. will post 0.28 EPS for the current year.

A number of analysts have commented on ZYXI shares. Zacks Investment Research upgraded Zynex from a “sell” rating to a “hold” rating in a research report on Thursday, June 27th. B. Riley boosted their target price on Zynex from $9.00 to $10.75 and gave the stock a “buy” rating in a research report on Friday, August 2nd.

Several large investors have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its position in shares of Zynex by 969.3% in the second quarter. JPMorgan Chase & Co. now owns 4,277 shares of the company’s stock valued at $37,000 after acquiring an additional 3,877 shares in the last quarter. Strs Ohio acquired a new position in Zynex in the second quarter valued at $37,000. WealthTrust Axiom LLC increased its stake in Zynex by 15.2% in the second quarter. WealthTrust Axiom LLC now owns 34,050 shares of the company’s stock valued at $306,000 after purchasing an additional 4,500 shares during the last quarter. D. E. Shaw & Co. Inc. acquired a new position in Zynex in the second quarter valued at $90,000. Finally, Zebra Capital Management LLC acquired a new position in Zynex in the second quarter valued at $91,000. Institutional investors and hedge funds own 0.05% of the company’s stock.

Zynex Company Profile

Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.

See Also: What is a Stop Order?

Insider Buying and Selling by Quarter for Zynex (OTCMKTS:ZYXI)

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.